See more : Vinyoflex Limited (VINYOFL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Stella Pharma Corporation (4888.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stella Pharma Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Abaxx Technologies Inc. (ABXX.NE) Income Statement Analysis – Financial Results
- Star Cement Limited (STARCEMENT.BO) Income Statement Analysis – Financial Results
- SMS Lifesciences India Limited (SMSLIFE.BO) Income Statement Analysis – Financial Results
- MediXall Group, Inc. (MDXL) Income Statement Analysis – Financial Results
- Schobrunn Paris SA (MLSCH.PA) Income Statement Analysis – Financial Results
Stella Pharma Corporation (4888.T)
About Stella Pharma Corporation
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 269.49M | 229.07M | 100.10M | 205.97M | 0.00 |
| Cost of Revenue | 52.19M | 22.12M | 15.24M | 24.19M | 29.05M |
| Gross Profit | 217.30M | 206.94M | 84.86M | 181.78M | -29.05M |
| Gross Profit Ratio | 80.63% | 90.34% | 84.78% | 88.25% | 0.00% |
| Research & Development | 393.00M | 374.00M | 255.00M | 307.00M | 441.37M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 571.00M | 625.00M | 555.00M | 539.00M | 951.00M |
| Other Expenses | 13.60M | 39.11M | 17.86M | 27.41M | 0.00 |
| Operating Expenses | 977.60M | 1.01B | 826.76M | 862.34M | 960.00M |
| Cost & Expenses | 1.03B | 1.04B | 842.00M | 886.54M | 960.00M |
| Interest Income | 1.44M | 1.43M | 146.00K | 8.00K | 0.00 |
| Interest Expense | 2.08M | 2.58M | 3.10M | 3.24M | 0.00 |
| Depreciation & Amortization | 35.04M | 35.05M | 34.13M | 31.45M | 951.00M |
| EBITDA | -723.85M | -738.34M | -726.86M | -621.70M | -7.83M |
| EBITDA Ratio | -268.60% | -322.33% | -726.16% | -301.84% | 0.00% |
| Operating Income | -760.30M | -806.78M | -741.90M | -680.57M | -951.00M |
| Operating Income Ratio | -282.12% | -352.20% | -741.19% | -330.42% | 0.00% |
| Total Other Income/Expenses | -676.00K | 30.80M | -22.19M | 24.18M | -8.35M |
| Income Before Tax | -760.98M | -775.97M | -764.09M | -656.39M | -960.00M |
| Income Before Tax Ratio | -282.38% | -338.75% | -763.36% | -318.69% | 0.00% |
| Income Tax Expense | 2.77M | 2.85M | 3.63M | 2.85M | 2.00M |
| Net Income | -763.75M | -778.82M | -767.72M | -659.24M | -962.00M |
| Net Income Ratio | -283.40% | -340.00% | -766.98% | -320.07% | 0.00% |
| EPS | -24.66 | -26.97 | -27.34 | -32.90 | -48.02 |
| EPS Diluted | -24.66 | -26.97 | -27.34 | -32.90 | -34.95 |
| Weighted Avg Shares Out | 30.98M | 28.88M | 28.08M | 20.03M | 20.03M |
| Weighted Avg Shares Out (Dil) | 30.98M | 28.88M | 28.08M | 20.03M | 27.53M |
Source: https://incomestatements.info
Category: Stock Reports